Human IL-2 as a vaccine adjuvant
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 1, 1998
Issued Date -
N/A
app pub date -
Oct 17, 1996
filing date -
Sep 20, 1985
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully